Bookmark this pageiconPrint this pageE-mail this page

This is an international site for FEMARA® (letrozole) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Femara and Breast Cancer Information for International Healthcare Professionals Femara and Breast Cancer Information for US residents Femara and Breast Cancer Information for Patients Outside the US

FEMARA® Safety Information

Contraindications: Hypersensitivity to letrozole or excipients. Premenopausal endocrine status; pregnancy, breast-feeding.

Precautions/Warnings: Careful consideration of risk/benefit in patients with creatinine clearance <10 mL/ min. Patients with severe hepatic impairment (Child-Pugh score C) should be kept under close supervision. Consider adequate contraception in women who have the potential to become pregnant, including women who are perimenopausal or who recently became postmenopausal, until postmenopausal status is fully established. Monitoring of bone health.

Adverse reactions:


Note: Before prescribing, please read full prescribing information.